This year’s agenda offers case studies that bridge both ever-present challenges of assay design and advanced de-risking strategies for the next generation of biomolecules. Our faculty helps you:
- • Optimize your risk minimization strategies to cover the entire preclinical-to-clinical life cycle
- • Create and capitalize on the most advanced transgenic animal models to get the best grasp on predicting immunogenicity
- • Identify the must-have features of molecular design to minimize or eliminate epitopes
- • Adapt your skills to the unique features of newly-developed varieties of biomolecules, including biosimilars, nanomedicines, bispecifics and antibody-drug conjugates
PLUS! Based on feedback from your industry peers, our 2013 agenda highlights include:
- • Three FDA keynote speakers - An in-depth insight from FDA regulators, featuring the release of draft guidelines for biosimilar development
- • Immunogenicity University - Back by popular demand, this intensive full-day summit dives into the fundamentals of immunogenicity assessment, statistical analysis and assay design – beneficial for experts at all levels of their career
- • Increased Networking Opportunities - You’ll have 8+ hours of networking opportunity, including a Wine and Cheese Reception where scientists can link-up with lab technicians, research providers and regulatory consultants
|
Share this article with your social network, just click below to share now!
|
|
|
No comments :
Post a Comment